Vogt-Koyanagi-Harada Disease

Sugiura, Saiko

doi:10.1007/978-3-642-88589-1_229

Cited by 96 publications

(92 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…VKH disease also leads e.g. to dysfunction of the inner ear, scalp supersensitivity and limbal vitiligo (Sugiura's sign) as minor com plications [3]. Clinical pictures in our cases were similar to those in the previous reports [8][9][10],…”

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Studies on Corticosteroid Therapy in Vogt-Koyanagi-Harada Disease

Sasamoto

Ohno

Matsuda³

1990

Ophthalmologica

View full text Add to dashboard Cite

We evaluated the significance of corticosteroid therapy on 47 new patients with Vogt-Koyanagi-Harada disease examined in the Uveitis Survey Clinic of the Hokkaido University Hospital. All patients were treated with topical corticosteroids, with or without systemic corticosteroids. 18 patients received systemic corticosteroid as pulse therapy, 20 patients received high-dose corticosteroid starting with prednisolone 200 mg, 2 patients received conventional-dose corticosteroid and 7 patients received no systemic corticosteroid therapy. When we evaluated the results 6 months after the initiation of treatment, anterior chamber inflammation was significantly less in patients with pulse and high-dose corticosteroid therapy than in those without systemic corticosteroid therapy. Furthermore, final visual acuity was significantly better in patients with pulse and high-dose corticosteroid than in those without them. However, there was no significant difference between patients with pulse therapy and those with high-dose corticosteroid therapy. The findings are in support of systemic corticosteroid therapy (pulse and high-dose) in the treatment of Vogt-Koyanagi-Harada disease.

show abstract

Section: Discussionsupporting

confidence: 85%

“…The exact cause of VKH disease is still unknown [2][3][4]. In the treatment of VKH disease, high-dose predni solone therapy was reported in 1969 in Japan [5].…”

Section: Introductionmentioning

confidence: 99%

Studies on Corticosteroid Therapy in Vogt-Koyanagi-Harada Disease

Sasamoto

Ohno

Matsuda³

1990

Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…However, it may be postulated that the human melanoma cells and normal melanocytes may share common antigenic determinants or antigenically cross-reactive components on their cell surfaces. It was surmised that the cell surface antigens of the normal melanocytes are altered by an unknown mechanism, and this may trigger destruction of the melano cytes in VKH [8], The present results indi cated that the cytotoxic T lymphocytes from the VKH patients do have the capability of specifically affecting the melanoma cells, and it is possible that the above opinion is applicable to the pathogenesis of VKH. Further investigations need to be carried out to elucidate the mechanism underlying this aspect of pathogenesis of this disease.…”

Section: Discussionsupporting

confidence: 53%

“…The diagnosis was confirmed on the basis of the typical clinical symptoms and findings by slitlamp examination, ophthalmosco py, fluorescein angiography and examinations of the cerebrospinal fluid [8], All the patients received sys temic corticosteroids in the acute stage, and at the time ol the present examination, they were in the convales cent stage and had not received corticosteroid for at least 1 month previously. 3 normal volunteers partici pated in this study as controls.…”

Section: Subjectsmentioning

confidence: 78%

See 1 more Smart Citation

The Role of Cytotoxic T Lymphocytes in the Pathogenesis of Vogt-Koyanagi-Harada Disease

et al. 1982

View full text Add to dashboard Cite

Peripheral blood lymphocytes (PBL) were isolated from blood of 6 patients with Vogt-Koyanagi-Harada disease (VKH), and their cytotoxic activity was assayed using ⁵¹Cr release from the labelled cells; the cytotoxicity was expressed as percentage release in reference to the complete release using saponin. The PBLs from the patients showed a significant cytotoxic activity against P-36 human melanoma cells, and the specificity of the reaction was confirmed by the cold target inhibition test and also by the use of HeLa-S3 human cervical carcinoma cells and B-16 mouse melanoma cells, since no significant cytotoxicity was seen against these cells. The cytotoxic activity was greatly reduced by pretreatment of the PBLs with monoclonal antihuman Leu-1 antibody plus the rabbit complement. It was, therefore, thought that the cytotoxic activity against the melanoma cells is mainly due to T cells. In addition, the cytotoxic activity was specifically blocked by monoclonal antihuman Leu-2a antibody, the specificity of which is distributed on cytotoxic/suppressor T cell subset of normal human peripheral lymphocytes and normal human thymocytes. A possibility was discussed as regards the involvement of the cytotoxic T lymphocytes in the pathogenesis of VKH.

show abstract

Bilateral Conjunctival Nodules: An Unusual Manifestation of Vogt-Koyanagi-HaradaSyndrome

Yang¹

2004

Arch Ophthalmol

View full text Add to dashboard Cite

Vogt-Koyanagi-Harada Disease

Cited by 96 publications

References 0 publications

Studies on Corticosteroid Therapy in Vogt-Koyanagi-Harada Disease

Studies on Corticosteroid Therapy in Vogt-Koyanagi-Harada Disease

The Role of Cytotoxic T Lymphocytes in the Pathogenesis of Vogt-Koyanagi-Harada Disease

Bilateral Conjunctival Nodules: An Unusual Manifestation of Vogt-Koyanagi-HaradaSyndrome

Contact Info

Product

Resources

About